iBio, Inc. (IBIO) News
Filter IBIO News Items
IBIO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IBIO News Highlights
- IBIO's 30 day story count now stands at 2.
- Over the past 21 days, the trend for IBIO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- CDMO and DEC are the most mentioned tickers in articles about IBIO.
Latest IBIO News From Around the Web
Below are the latest news stories about IBIO INC that investors may wish to consider to help them evaluate IBIO as an investment opportunity.
iBio Amends and Extends Maturity of Credit Agreement– Extends maturity date to March 29, 2024 – – Allows for more time to complete planned divestiture of legacy CDMO business - BRYAN, Texas and SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced its wholly owned subsidiary, iBio CDMO LLC, and its lender, Woodforest National Bank (“Woodforest”), have entered into an amendment (the “Amendment”) to the Credit Agreement dated Nove |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time to dive into the biggest pre-market stock movers as we check out all of the hottest trading news for Tuesday morning! |
Piper Sandler Is Souring on Albemarle (ALB) StockAlbemarle stock is falling on Tuesday alongside a downgrade and price target reduction for ALB shares from a Piper Sandler analyst. |
Why Is iBio (IBIO) Stock Down 41% Today?Ibio stock is falling on Tuesday after the biotechnology company announced the pricing of its shares in a public offering. |
Why Is SilverSun Technologies (SSNT) Stock Down 28% Today?SilverSun Technologies stock is falling on Tuesday but that's only due to shares of SSNT giving up ground that was gained on Monday. |
iBio, Inc. Announces Pricing of $4.5 Million Public OfferingBRYAN, Texas and SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), today announced the pricing of its reasonable best efforts public offering of 2,250,000 of its shares of common stock (or common stock equivalents in lieu thereof) and accompanying Series C and Series D warrants to purchase up to an aggregate of 2,250,000 shares of common stock at a combined public offering price of $2.00, resulting in gross proceeds of approximately $4.5 million. The |
iBio Announces Reverse Stock SplitBRYAN, Texas and SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) today announced that its Board of Directors has approved a 20-to-1 reverse split of the Company’s common stock, par value $0.001 per share (the “Common Stock”) effective at 12:01 a.m. ET on November 29, 2023 (the “Effective Date”). The Common Stock is expected to begin trading on a split-adjusted basis when the market opens on November 29, 2023, with the new CUSIP number 451033708. The |
iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific- ShieldTx potentially increases safety and developability of therapeutic antibodies for difficult targets and modes of action - BRYAN, Texas and SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) today announced the expansion of its AI-powered technology stack with the launch of ShieldTx, a patent-pending antibody masking technology designed to enable specific, highly targeted antibody delivery to diseased tissue without harming healthy tissue. By add |
iBio to Highlight Technology for Advancing Discovery of Bispecifics at Festival of Biologics- VP of Platform Technologies, Matt Greving, to present data on enhancing T-cell engagers using machine-learning guided epitope steering and mammalian display antibody libraries - BRYAN, Texas and SAN DIEGO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that Matt Greving Ph.D., its Vice President of Platform Technologies and Machine Learning, has been selected to present on the Co |
iBio Explains Recent Filing of Registration Statement– No new securities are being registered under the Post-Effective Amendment –BRYAN, Texas and SAN DIEGO, Oct. 02, 2023 (GLOBE NEWSWIRE) -- In response to investor inquiries received about the post-effective amendment to its Form S-3 on Form S-1 (the “Post-Effective Amendment”) filed on Friday, September 29, 2023 with the United States Securities and Exchange Commission (“SEC”), iBio Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today p |